A-SEEDS
Development of non-viral CAR-T cell therapies for intractable cancers, utilizing a proprietary piggyBac transposon gene transfer method.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $3.0m | Seed | |
| Total Funding | 000k | ||
Related Content
A-SEEDS is a Japanese biotech company that spun out of Shinshu University, specializing in the development of CAR-T cell therapy for cancer treatment. The company is focused on creating new treatment options for patients with intractable cancers.
A-SEEDS' core technology revolves around a proprietary, non-viral gene transfer method using the piggyBac transposon system. This approach is intended to improve the safety and efficiency of CAR-T cell production compared to conventional viral vector methods. The company's business model is centered on the research, development, and eventual commercialization of these novel cancer therapies. They have recently secured significant Series A funding to advance their pipeline products into clinical trials.
The company collaborates with academic institutions and other partners to accelerate its research and development efforts. By focusing on autologous CAR-T therapy, A-SEEDS aims to provide personalized treatment solutions for cancer patients.
Keywords: CAR-T cell therapy, oncology, biotechnology, gene therapy, cancer treatment, piggyBac transposon, immunotherapy, life sciences, clinical trials, personalized medicine